STOCK TITAN
  1. Home
  2. News
  3. AUPH

Aurinia Pharmaceuticals Inc - AUPH STOCK NEWS

Welcome to our dedicated page for Aurinia Pharmaceuticals news (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals stock.

Aurinia Pharmaceuticals Inc (symbol: AUPH) is a cutting-edge biopharmaceutical company headquartered at 5120-75 street, Edmonton, Canada. Specializing in the treatment of serious diseases with high unmet medical need, Aurinia is committed to providing innovative therapeutic solutions to patients worldwide. The company's flagship product, LUPKYNIS (voclosporin), is an investigational drug designed for the treatment of lupus nephritis (LN), a severe renal complication of lupus. This groundbreaking treatment underscores Aurinia's focus on developing life-changing medications.

In recent years, Aurinia Pharmaceuticals has made significant strides in its research and development efforts, particularly in the United States, where it derives the majority of its revenue. The company has forged strategic partnerships with leading healthcare organizations and continues to explore new avenues for growth and innovation.

Financially, Aurinia has demonstrated strong performance, with consistent revenue growth driven by its robust pipeline of investigational drugs. The company's commitment to advancing its clinical programs and securing regulatory approvals positions it well for sustained success in the biopharmaceutical industry.

With a dedicated team of experts and a clear vision for the future, Aurinia Pharmaceuticals is poised to make a lasting impact on global healthcare. Investors and stakeholders can stay updated on the latest developments, financial results, and strategic initiatives through the company's regular news updates and investor relations communications.

News

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan

Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced that its collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) in Japan. This follows the FDA approval of voclosporin in the U.S. for the treatment of adult patients with active LN. The collaboration agreement also includes potential royalties for Aurinia upon approval in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
-
News

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

Rhea-AI Summary
Aurinia Pharmaceuticals Inc. presented five studies at the annual American College of Rheumatology Convergence 2023, reinforcing the safety and effectiveness of LUPKYNIS® (voclosporin) for the treatment of adult patients with active lupus nephritis. The data showed improved safety and efficacy outcomes compared to conventional regimens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

Rhea-AI Summary
Aurinia Pharmaceuticals presented nine studies at the American Society of Nephrology Kidney Week 2023 Convergence. The studies reinforced the safety and effectiveness of LUPKYNISⓇ for the treatment of adult patients with active LN. A repeat kidney biopsy sub-study showed improvement in histologic activity without chronic injury. A propensity analysis suggested that LUPKYNISⓇ plus standard of care reduced toxicities and demonstrated earlier reductions in proteinuria. Black patients experienced improved outcomes with LUPKYNISⓇ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
none
News

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported a net product revenue of $40.8 million for Q3 2023, a 60% increase compared to the same period last year. The total net revenue for the nine months ended September 30, 2023, was $130.4 million, a 24% increase over the prior year. The company achieved a pricing and reimbursement milestone, triggering a $10 million payment from Otsuka Pharmaceutical Co. Ltd. They have narrowed their net product revenue guidance for 2023 to a range of $155 - $160 million. The company also highlighted the full results from AURORA 2, demonstrating kidney preservation and additional efficacy of LUPKYNIS. They appointed three new directors to the Board of Directors and provided updates on LUPKYNIS product performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.52%
Tags
earnings
-
News

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

Rhea-AI Summary
Aurinia Pharmaceuticals welcomes the updated recommendations from EULAR for the management of lupus nephritis. The recommendations suggest considering LUPKYNIS as a new treatment paradigm and highlight the importance of early intervention and combination therapies. They also recommend a lower maintenance dose of steroids and vigilant monitoring for new organ damage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
News

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

Rhea-AI Summary
Aurinia Pharmaceuticals to release Q3 2023 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
News

CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

Rhea-AI Summary
Aurinia Pharmaceuticals to release third quarter financial and operational results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
-
News

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)

Rhea-AI Summary
Aurinia Pharmaceuticals announces data presentations at upcoming medical conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
-
News

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

Rhea-AI Summary
Aurinia Pharmaceuticals appoints Dr. Robert T. Foster to the Board and enters into a cooperation agreement with MKT Capital. Dr. Foster brings deep biotech leadership experience and will contribute to the strategic review and commercialization of LUPKYNIS. Recent governance enhancements and the initiation of a strategic review are expected to create meaningful value for shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
management
News

Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines

Rhea-AI Summary
Aurinia Pharmaceuticals appoints Dr. Karen Smith and Jeffrey A. Bailey to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
management acquisition

FAQ

What is the current stock price of Aurinia Pharmaceuticals (AUPH)?

The current stock price of Aurinia Pharmaceuticals (AUPH) is $9.03 as of December 20, 2024.

What is the market cap of Aurinia Pharmaceuticals (AUPH)?

The market cap of Aurinia Pharmaceuticals (AUPH) is approximately 1.3B.

What does Aurinia Pharmaceuticals Inc. specialize in?

Aurinia Pharmaceuticals specializes in developing treatments for serious diseases with high unmet medical need, including lupus nephritis.

Where is Aurinia Pharmaceuticals Inc. located?

Aurinia Pharmaceuticals Inc. is headquartered at 5120-75 street, Edmonton, Canada.

What is LUPKYNIS (voclosporin)?

LUPKYNIS (voclosporin) is an investigational drug developed by Aurinia for the treatment of lupus nephritis.

Where does Aurinia Pharmaceuticals derive most of its revenue?

Aurinia Pharmaceuticals derives the majority of its revenue from the United States.

What recent achievements has Aurinia Pharmaceuticals accomplished?

Aurinia has made significant progress in its R&D efforts, particularly with LUPKYNIS, and has formed strategic partnerships to advance its clinical programs.

How can investors stay updated on Aurinia Pharmaceuticals' latest news?

Investors can stay updated through the company's regular news updates and investor relations communications.

What is the significance of LUPKYNIS for Aurinia Pharmaceuticals?

LUPKYNIS is a key product in Aurinia's portfolio, targeting lupus nephritis and showcasing the company’s innovative capabilities.

What type of diseases does Aurinia Pharmaceuticals focus on?

Aurinia focuses on serious diseases with a high unmet medical need, such as lupus nephritis.

Has Aurinia Pharmaceuticals formed any partnerships?

Yes, Aurinia has formed strategic partnerships with leading healthcare organizations to advance its clinical programs.

What is the outlook for Aurinia Pharmaceuticals’ future?

With a robust pipeline and ongoing R&D efforts, Aurinia Pharmaceuticals is well-positioned for sustained success in the biopharmaceutical industry.

Stock AUPH logo
Aurinia Pharmaceuticals Inc

Nasdaq:AUPH

AUPH Rankings

#2321 Ranked by Market Cap
N/A Ranked by Dividends

AUPH Stock Data

1.30B
132.45M
7.21%
42.72%
4.8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
EDMONTON